Abstract
Allogeneic hematopoietic Stem Cell Transplantation (ASCT) is well established as a curative treatment for many hematological malignancies and non-malignant disorders. The aim of ASCT in these diseases is to achieve sustained donor engraftment to fight leukemic cells in malignant disease, improve hematopoietic function, provide immune competence or normalize enzyme deficiency. Peripheral blood or bone marrow is commonly used to monitor engraftment after ASCT. The presence of mixed donor/recipient chimerism after transplantation, donor/donor chimerism after double cord blood transplantation can be used and interpreted differently based on the initial disease status. In patients with malignant diseases, chimerism is primarily used to detect early relapse but can also indicate threatening rejection. In individuals with non malignant disease, chimerism is merely used to monitor successful engraftment. After double cord blood transplantation, the unique situation with two existing donor immune systems can occur. Most often one of the immune systems rapidly succumbs with one immune system prevailing, but in certain situations mixed donor/donor chimerism can exist for prolonged periods. This review describes the importance of mixed chimerism and the possible interpretation after ASCT in patients with both malignant and non-malignant diseases. It also focuses specifically on the situation and mechanisms donor/ donor chimerism after double cord blood transplantation.
Highlights
Allogeneic hematopoietic Stem Cell Transplantation (ASCT) is well established as a curative treatment for many hematological malignancies and non-malignant disorders
SCT was performed with bone marrow and subsequently peripheral blood as stem cell source [4]
The post-transplant management of allogeneic SCT is associated with several lethal complications
Summary
Allogeneic Stem Cell Transplantation (SCT) is used as a curative treatment for leukemic malignancies, genetic defects in metabolism or immune function and certain solid tumors [1,2,3]. SCT was performed with bone marrow and subsequently peripheral blood as stem cell source [4]. The post-transplant management of allogeneic SCT is associated with several lethal complications. The decrease in immune function post transplant often results in opportunistic viral, bacterial and/or fungal infections [7,10,11]. Due to these complications the immunosuppressive management must be closely monitored in order not to unnecessarily extend or worsen this crucial period [12,13]. Infections can be monitored and fought with standard antimicrobial regiments, common in many hospital routines, while rejection and GVHD demand more specialized immunological methods and therapies [15,16,17]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
